Verona Pharma Plc (VRNA)

[Roger1]

Hopefully next week. Thanks for asking. 

[powerwalker]

Roger, thank you for the article. How is your pursuit to utilize ensifentrine going?

[Roger1]

https://share.newsbreak.com/9lxcziaz

Happy to see this. 

[powerwalker]

Thank you, Hoskuld. Looking forward to next Monday, November 4th.

[MegaPirate61]

Did we know the next weekly oct 18 script info yet?

[Hoskuld]

Sometimes it is difficult to say what option trades indicate - options are often part of hedging strategies. I am bullish on VRNA but these options sales/purchases could signify different expectations or similar expectations...who knows?

[powerwalker]

It looks as if someone (not me) is interested in the March 2025 $30 calls. There were 90 contracts traded yesterday and 40 today. Hope the buyer is right!

[Hoskuld]

We should have 10/18 and 10/24 script data by then...

[powerwalker]

Thank you, Hoskuld.

Verona cc on 11/4 with Q3 stats ... hopefully, it is a good sign being first thing on a Monday morning. They are anxious to talk!

[Hoskuld]

Yes - 324 week ending 10/11

[powerwalker]

Hoskuld, does that mean the scripts are over 300? Higher?

TYIA

[Hoskuld]

Scripts are trending up strongly now - more than 3x 4 weeks ago.

[Hoskuld]

IMO $70-$100 by the end of 2025.

[powerwalker]

All the best, Roger.

I sent message via its web site over the weekend asking about Marketing here in the States. I'll let you know when I hear back from them.

[Roger1]

Still in process of getting it. Delay is on my end with my Dr. Should be resolved next month with new doc. I can tell you that Verona reached out to me almost immediately after my inquiry in August and have texted and emailed since. They have been very responsive. Very positive feelings about this company. 

[powerwalker]

So, Roger, are you using Ohtuvayre? If so, is it meeting your expectations? TYIA

[Roger1]

Acaria Health is one of the fulfillment pharmacies. They are handling me.

[powerwalker]

Roger, Hoskuld has access to such data but did not specify the numbers. See post #214.

[Roger1]

Do. you have a link to your info by any chance? Release,  conference,  etc? TIA

[powerwalker]

Thank you, Hoskuld, for the information.

Do you have any numbers to share ... and get some people excited. TYIA

[Hoskuld]

Prescription fulfillment is finally accelerating. Buckle up.

[Hoskuld]

That is great GB!

[gbrown6332]

Saw your original post on VRNA. Sounded good. Decided to tag along. Glad I did.

Thks,

G. Brown

[powerwalker]

Someone certainly does not want this stock to go and stay above $28.

[Hoskuld]

Got it - you meant pharmacies not pharmas (which are drug manufacturing companies.) Makes sense. I will actually check to see if ohtuvayre is at local CVS this week!

I can imagine you would be excited about this and I am really looking forward to hearing about your experience with it! Thanks for sharing!

[Roger1]

Btw, I didn't say it wasn't going well. I said it takes time for any new drug given the logistics. I think they're doing a great job or i wouldn't have invested in them.

[Roger1]

Checked out the drug with CVS and was told about specialty pharmas. I'm a COPD patient and respiratory therapist and have followed trials for quite a while and am delighted to try this drug. Was told the same thing by Verona when I signed up for the drug through the patient portal. I used to teach the mechanism of action of bronchodilators. Specifically C3-5AMP . Taught therapists, nurses, and many of the older physicians sat in for refresher.
Check with your pharmacist and see if it's available. I'd be interested in your findings.

[Hoskuld]

They were already detailing 100 of the top 2,500 pulmonologists as of 2 weeks ago, and presumably are detailing ~20-25 more each week. The launch is already going well.

What did you mean by "speciality pharmas until then"?

[Roger1]

I think it will be January b4 the roll out is complete. Specialty pharmas until then. Have patience, this drug will be a blockbuster with its double mechanism of action.

[Hoskuld]

Hi PW - the company has said that they are looking to partner ohtuvayre in the EU and, as a part of that partnership, the partner would be responsible for developing an inhaler for ohtuvayre, too.

I agree that the company management seems sharp. And all newly launched products have issues - let's hope Verona is on top of the issues. I wrote IR and simply asked that they send me a note saying that my message was received and the responsible people at Verona are "on it".

[powerwalker]

Hoskuld, I listened to the quarterly cc and the Canaccord Genuity presentation and I came away with the impression that Verona management is on top of all matters: marketing, sales, and distribution. If there were a problem, it might be the pharmacies listing Ohtuvayre in their systems, given it is a new product and it needs to establish an ordering pattern for it.

Hoping the patient numbers are higher within a year.

Have you seen or heard any info on EMA and/or UK filings/approval?

[Hoskuld]

Just following up on this...I can see ohtuvayre being the SOC. I think this will grow very, very swiftly.

[Hoskuld]

A couple of pulmonologists on stocktwits describe issues with scripts that they have written being fulfilled. On the other hand, one of the pulmonologists is writing 5-6 scripts per day and the other seemed to be writing 2 per day. 5-6 per day = 1,000+ per year for one high-prescribing pulmonologist. And ~400 for a less aggressive prescriber. To me, those seem like promising numbers and point to hitting 60,000+ plus patients over the next year as being probable and NOT a stretch.

[Hoskuld]

Luckily, we know the story here.

[powerwalker]

Not actually a "Hit" piece, but leaves negative impressions, anyway. Released earlier in late July ... must not have had the intended effect, so it tries again.

Top 3 Health Care Stocks That May Crash In August

https://www.benzinga.com/news/24/08/40365322/top-3-health-care-stocks-that-may-crash-in-august

[Hoskuld]

Glad you are making money here k9uwa! I think we will see this go much higher over the next couple of years. Would really like to get access to script data...

[k9uwa]

Hope everyone is buckled in and enjoying the ride. I Am Wishing I had put another zero onto my purchase on this one.
Thanks U and Guzzie
John k9uwa

[Hoskuld]

Anyone have IMS / IQVIA script data access for Ohtuvayre? Has been a few weeks and this is doing exactly what it should do. Hope everyone is buckled in and enjoying the ride.

[Golden Cross]

$VRNA COPD drug approved
- 1st-in-class neb PDE4 inhibitor
- antinflamm + b-dilator
- Clean, broad label, no restrictions
- Complements ICS LABA LAMA, doesn't compete
- Targets broad COPD population vs. narrow biologics like Dupixent
- Big Pharma (Boehringer, GSK) easy bolt-on addition to pipeline

[Golden Cross]

$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)https://t.co/6gOmzKSwx2

— 💸 Golden Cross Stocks 💸 (@CrossStocks) June 26, 2024

[HMB2010]

In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize ensifentrine in Greater China. On April 6th 2023, Nuance Pharma announced first patient in (FPI) for the ENHANCE-China Phase III clinical trial.

https://finance.yahoo.com/news/nuance-pharmas-partner-verona-pharma-090700900.html

Should be good return here!

[stock1ace1]

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine

[Golden Cross]

so is the price already figured in or what here

[Golden Cross]

$VRNA awaits FDA decision on June 26 for ensifentrine, a groundbreaking COPD therapy. With $901.89M in cash, they’re set for a strong future. Approval could make ensifentrine the first new inhaled #COPD treatment in 20+ years!

[PonkenPlonken]

Today, we have entered into two strategic financing agreements with Oaktree and OMERS, providing access to up to $650M to support the potential US launch of #ensifentrine and the expansion of its clinical activities.
Read more here: https://t.co/vF5GOXjXtN$VRNA pic.twitter.com/pRMLsHPe0t

— Verona Pharma (@VeronaPharma) May 9, 2024

this does not look like Ensifentrine is expected to fail.

[Amatuer17]

https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent-ensifentrine-is-a-breath-of-fresh-air

Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.

Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.

[4Godnwv]

Great news today AH - this little pharm might be going places.

[TheFinalCD]

25.77

[Amatuer17]

COPD is a crowded place - not sure about what is special about their drug?

Unless this drug is better than other COPD drugs - this co is fully priced @ $2 B

This co cannot market the product even if approved - so it needs to be bought out but it will not get more than $3 B - so maybe 50% premium from here

[Laster]

Very few sure bets on Nasdaq.
But I think it is a safe bet that this company will be bought out in 2023. Significantly high stock price.
Patience will pay off here.
JMO.